Updated:
Biotex
Founded in 1998 and based in Houston, Biotex operates as a contract development and manufacturing organization (CDMO) for medical devices.
Biotex
Founded in 1998 and based in Houston, Biotex operates as a contract development and manufacturing organization (CDMO) for medical devices. It serves an array of physician-inventors, early-stage startups, and established healthcare companies. The firm provides an integrated development environment, guiding a device from concept to market by combining engineering, quality, regulatory, and manufacturing competences under one roof. Sourced from its own operational record, Biotex points to the creation and subsequent sale of its spin-out Visualase—an MRI-guided laser ablation system—to Medtronic as a marker of its ability to build and exit medical technology companies. Biotex addresses a wide asset-class mix within medical devices, spanning diagnostic hardware, sterile cordless surgical tools (such as the Phasor Health cordless drill), nanoscale laboratory analysis technology (including the Redpoint ultra-sensitive device), and thermal ablation systems. Its investment strategy is expressed through direct engineering services and manufacturing scale-up rather than traditional fund commitments. The firm participates in clinical-trial design and management, regulatory submission strategy, and commercial manufacturing. It supports projects across multiple geographies, including the United States and Canada, as reflected in its FDA registration and Toronto-linked records. A distinct feature is its willingness to take equity-based compensation in client ventures, alongside traditional time-and-materials and fixed-price models. Team size remains undisclosed, though the firm describes a multidisciplinary group with in-house regulatory specialists, engineers, and an ISO/IEC 17025–accredited testing laboratory, Criterion. Biotex does not disclose a flagship fund or traditional AUM, consistent with its operating-business structure. No adjacent philanthropic vehicles, club memberships, or public executive team listings are available to clarify its wealth-origin or governance structure. The firm has not published a notable operational restructuring or promotion in the last 24 months.
General information
Firm type
Single Family Office
Year founded
1998
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Houston
Corporate office
114 Holmes Rd, Houston, Texas 77045, United States
Sector focus
Frequently asked questions
How does Biotex source its deal flow?
Biotex sources its projects through direct engagement with physician-inventors, early-stage healthcare startups, and established medical device companies. Its business model is built on being a technical and operational partner rather than a passive investor, and its marketing emphasizes converting a clinician's insight into a commercial device. The firm's physical footprint in Houston, near the world's largest medical center, positions it to capture ideas directly from practicing physicians and surgeons.
Is Biotex a single-family office investment vehicle or an operating company?
Biotex presents itself as an operating company and contract development and manufacturing organization (CDMO) for medical devices. While Altss classifies it as a single-family office based on the firm's undisclosed ownership structure and investment in its own portfolio companies, its public posture is that of a hands-on service provider. It does not publicly market itself as a family office or an investment fund, and it has never disclosed a pool of third-party capital.
Does Biotex participate in fund commitments or only direct deals?
Biotex participates only in direct deals structured as service agreements for a fee, a slice of equity, or both. The firm's client intake form explicitly lists equity as an accepted compensation model, indicating a willingness to take a direct ownership stake in the projects it develops. There is no public evidence that Biotex acts as a limited partner in external venture capital or private equity funds.
What is Biotex's known posture on co-investments alongside external GPs?
Biotex's standard model does not involve co-investing with external general partners. Its co-investment-like alignment comes from exchanging services for equity in client companies. The firm acts as the primary operational and technical partner for its portfolio of incubated and accelerated projects rather than joining a syndicate led by another investor.
How does Biotex handle regulatory risk and FDA approval for its portfolio companies?
Regulatory navigation is a core pillar of Biotex's service offering. The firm maintains an FDA-registered facility, an ISO 13485:2016 certified quality system, and an in-house ISO/IEC 17025–accredited testing lab called Criterion. It offers a full range of services from pre-clinical testing and clinical trial management to regulatory submission, aiming to de-risk the pathway to market for its partner companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: